

DAFTAR PUSTAKA

- ASA, S. L. (2005) The Pathology of Thyroid Cancer. IN FARID, N. R. (Ed.) *Molecular Basis of Thyroid Cancer*. Boston, Kluwer Academic Publishers, 23-37.
- BRYSON, P. C., SHORES, C. G., HART, C., THORNE, L., PATEL, M. R., RICHEY, L., FARAG, A. & ZANATION, A. M. (2008) Immunohistochemical distinction of follicular thyroid adenomas and follicular carcinomas. *Arch Otolaryngol Head Neck Surg*, 134, 581-6.
- CHAN, J. K. C., HIROKAWA, M., EVANS, H., WILLIAMS, E. D., OSAMURA, Y., CADY, B., SOBRINHO-SIMÕES, M., DERWAHI, M., PASCHKE, R., BELGE, G., ORIOLA, J., STUDER, H., ENG, C., ASA, S. L., LLOYD, R. V., BALOCH, Z., GHOSSEIN, R., MAZZAFERRI, E. & FAGIN, J. A. (2004) Follicular Adenoma IN DELELLIS, R. A., LLOYD, R. V., HEITZ, P. U. & ENG, C. (Eds.) *World Health Organization Classification of Tumours. Pathology & Genetics Tumours of Endocrine organs*. Lyon, IARC Press, 98-103.
- CHEUNG, C. C., EZZAT, S., FREEMAN, J. L., ROSEN, I. B. & ASA, S. L. (2001) Immunohistochemical diagnosis of papillary thyroid carcinoma. *Mod Pathol*, 14, 338-42.
- CHIU, C. G., STRUGNELL, S. S., GRIFFITH, O. L., JONES, S. J., GOWN, A. M., WALKER, B., NABI, I. R. & WISEMAN, S. M. (2010) Diagnostic utility of galectin-3 in thyroid cancer. *Am J Pathol*, 176, 2067-81.
- COLLET, J. F., HURBAIN, I., PRENGEL, C., UTZMANN, O., SCETBON, F., BERNAUDIN, J. F. & FAJAC, A. (2005) Galectin-3 immunodetection in follicular thyroid neoplasms: a prospective study on fine-needle aspiration samples. *Br J Cancer*, 93, 1175-81.
- CVEJIC, D. S., SAVIN, S. B., PETROVIC, I. M., PAUNOVIC, I. R., TATIC, S. B. & HAVELKA, M. J. (2005) Galectin-3 expression in papillary thyroid carcinoma: relation to histomorphologic growth pattern, lymph node metastasis, extrathyroid invasion, and tumor size. *Head Neck*, 27, 1049-55.
- DE MATOS, P. S., FERREIRA, A. P., DE OLIVEIRA FACURI, F., ASSUMPCAO, L. V., METZE, K. & WARD, L. S. (2005) Usefulness of HBME-1, cytokeratin 19

and galectin-3 immunostaining in the diagnosis of thyroid malignancy. *Histopathology*, 47, 391-401.

- DELELLIS, R. A. & WILLIAMS, E. D. (2004) Thyroid and Parathyroid tumours: Introduction. IN DELELLIS, R. A., LLOYD, R. V., HEITZ, P. U. & ENG, C. (Eds.) *World Health Organization Classification of Tumours. Pathology and Genetics Tumours of Endocrine Organs*. Lyon, IARC Press, 49-56.
- DUMIC, J., DABELIC, S. & FLOGEL, M. (2006) Galectin-3: an open-ended story. *Biochim Biophys Acta*, 1760, 616-35.
- INOHARA, H., SEGAWA, T., MIYAUCHI, A., YOSHII, T., NAKAHARA, S., RAZ, A., MAEDA, M., MIYOSHI, E., KINOSHITA, N., YOSHIDA, H., FURUKAWA, M., TAKENAKA, Y., TAKAMURA, Y., ITO, Y. & TANIGUCHI, N. (2008) Cytoplasmic and serum galectin-3 in diagnosis of thyroid malignancies. *Biochem Biophys Res Commun*, 376, 605-10.
- ITO, Y., YOSHIDA, H., TOMODA, C., MIYA, A., KOBAYASHI, K., MATSUZUKA, F., YASUOKA, H., KAKUDO, K., INOHARA, H., KUMA, K. & MIYAUCHI, A. (2005) Galectin-3 expression in follicular tumours: an immunohistochemical study of its use as a marker of follicular carcinoma. *Pathology*, 37, 296-8.
- JEMAL, A., BRAY, F., CENTER, M. M., FERLAY, J., WARD, E. & FORMAN, D. (2011) Global cancer statistics. *CA Cancer J Clin*.
- JEMAL, A., SIEGEL, R., XU, J. & WARD, E. (2010) Cancer statistics, 2010. *CA Cancer J Clin*, 60, 277-300.
- KIM, H. R., LIN, H. M., BILIRAN, H. & RAZ, A. (1999) Cell cycle arrest and inhibition of anoikis by galectin-3 in human breast epithelial cells. *Cancer Res*, 59, 4148-54.
- KONDO, T., EZZAT, S. & ASA, S. L. (2006) Pathogenetic mechanisms in thyroid follicular-cell neoplasia. *Nat Rev Cancer*, 6, 292-306.
- KRZESLAK, A. & LIPINSKA, A. (2004) Galectin-3 as a multifunctional protein. *Cell Mol Biol Lett*, 9, 305-28.
- LAVRA, L., ULIVIERI, A., RINALDO, C., DOMINICI, R., VOLANTE, M., LUCIANI, E., BARTOLAZZI, A., FRASCA, F., SODDU, S. & SCIACCHITANO, S. (2009) Gal-3 is stimulated by gain-of-function p53 mutations and modulates chemoresistance in anaplastic thyroid carcinomas. *J Pathol*, 218, 66-75.

- LEVY, R., GRAFI-COHEN, M., KRAIEM, Z. & KLOOG, Y. (2010) Galectin-3 promotes chronic activation of K-Ras and differentiation block in malignant thyroid carcinomas. *Mol Cancer Ther*, 9, 2208-19.
- LIN, C. I., WHANG, E. E., ABRAMSON, M. A., DONNER, D. B., BERTAGNOLLI, M. M., MOORE, F. D., JR. & RUAN, D. T. (2009) Galectin-3 regulates apoptosis and doxorubicin chemoresistance in papillary thyroid cancer cells. *Biochem Biophys Res Commun*, 379, 626-31.
- LIU, Y. Y., MORREAU, H., KIEVIT, J., ROMIJN, J. A., CARRASCO, N. & SMIT, J. W. (2008) Combined immunostaining with galectin-3, fibronectin-1, CITED-1, Hector Battifora mesothelial-1, cytokeratin-19, peroxisome proliferator-activated receptor- γ , and sodium/iodide symporter antibodies for the differential diagnosis of non-medullary thyroid carcinoma. *Eur J Endocrinol*, 158, 375-84.
- LIVOLSI, V. A., ALBORES-SAAVEDRA, J., ASA, S. L., BALOCH, Z. W., SOBRINHO-SIMÕES, M., WENIG, B., DELELLIS, R. A., MAZZAFERRI, E. L., HAY, I., FAGIN, J. A., WEBER, A. L., CARUSO, P., VOULTILAINEN, P. E., FRANSILLA, B., WILLIAMS, E. D., SCHNEIDER, A. B., NIKIFOROV, Y. E., RABES, H. M., AKSLEN, L., EZZAT, S., SANTORO, M., ENG, C. Y. & HARACH, R. (2004) Papillary Carcinoma. IN DELELLIS, R. A., LLOYD, R. V., HEITZ, P. U. & ENG, C. (Eds.) *World Health Organization Classification of tumours. Pathology & Genetics. Tumours of Endocrine*. Lyon, IARC Press, 57-66.
- LONDERO, S. C., GODBALLE, C., KROGDAHL, A., BASTHOLT, L., SPECHT, L., SORENSEN, C. H., PEDERSEN, H. B., PEDERSEN, U. & CHRISTIANSEN, P. (2008) Papillary microcarcinoma of the thyroid gland: is the immunohistochemical expression of cyclin D1 or galectin-3 in primary tumour an indicator of metastatic disease? *Acta Oncol*, 47, 451-7.
- MAITRA, A. (2010) The Endocrine System. IN KUMAR, V., ABBAS, A. K., FAUSTO, N. & ASTER, J. C. (Eds.) *Robbins and Cotran Pathologic Basis of Disease*. 8th ed. Philadelphia, Saunders Elsevier, 8, 1097-164.
- MATIAS-GUIU, X., DELELLIS, R. A., MOLEY, J. F., GAGEL, R. F., ALBORES-SAAVEDRA, J., BUSSOLATI, G., KASERER, E. D. & BALOCH, Z. (2004)

- Medullary Thyroid Carcinoma. IN DELELLIS, R. A., LLOYD, R. V., HEITZ, P. U. & ENG, C. (Eds.) *World Health Organization Classification of Tumours. Pathology & Genetics Tumours of Endocrine Organs*. Lyon, IARC Press, 86-91.
- NAKAHARA, S., OKA, N. & RAZ, A. (2005) On the role of galectin-3 in cancer apoptosis. *Apoptosis*, 10, 267-75.
- NANGIA-MAKKER, P., BALAN, V. & RAZ, A. (2008) Regulation of tumor progression by extracellular galectin-3. *Cancer Microenviron*, 1, 43-51.
- PARK, Y. J., KWAK, S. H., KIM, D. C., KIM, H., CHOE, G., PARK DO, J., JANG, H. C., PARK, S. H., CHO, B. Y. & PARK, S. Y. (2007) Diagnostic value of galectin-3, HBME-1, cytokeratin 19, high molecular weight cytokeratin, cyclin D1 and p27(kip1) in the differential diagnosis of thyroid nodules. *J Korean Med Sci*, 22, 621-8.
- PRASAD, M. L., PELLEGGATA, N. S., HUANG, Y., NAGARAJA, H. N., DE LA CHAPELLE, A. & KLOOS, R. T. (2005) Galectin-3, fibronectin-1, CITED-1, HBME1 and cytokeratin-19 immunohistochemistry is useful for the differential diagnosis of thyroid tumors. *Mod Pathol*, 18, 48-57.
- RIESCO-EIZAGUIRRE, G. & SANTISTEBAN, P. (2007) New insights in thyroid follicular cell biology and its impact in thyroid cancer therapy. *Endocr Relat Cancer*, 14, 957-77.
- RINGEL, M. D. (2005) Diagnostic Molecular Markers in Thyroid Cancer. IN FARID, N. R. (Ed.) *Molecular Basis of Thyroid Cancer*. Boston, Kluwer Academic Publisher, 295-316.
- RORIVE, S., EDDAFALI, B., FERNANDEZ, S., DECAESTECKER, C., ANDRE, S., KALTNER, H., KUWABARA, I., LIU, F. T., GABIUS, H. J., KISS, R. & SALMON, I. (2002) Changes in galectin-7 and cytokeratin-19 expression during the progression of malignancy in thyroid tumors: diagnostic and biological implications. *Mod Pathol*, 15, 1294-301.
- ROSSI, E. D., RAFFAELLI, M., MULE, A., MIRAGLIA, A., LOMBARDI, C. P., VECCHIO, F. M. & FADDA, G. (2006) Simultaneous immunohistochemical expression of HBME-1 and galectin-3 differentiates papillary carcinomas from hyperfunctioning lesions of the thyroid. *Histopathology*, 48, 795-800.

- RUGGERI, R. M., CAMPENNI, A., BALDARI, S., TRIMARCHI, F. & TROVATO, M. (2008) What is New on Thyroid Cancer Biomarkers. *Biomark Insights*, 3, 237-252.
- SAPIO, M. R., GUERRA, A., POSCA, D., LIMONE, P. P., DEANDREA, M., MOTTA, M., TRONCONE, G., CALEO, A., VALLEFUOCO, P., ROSSI, G., FENZI, G. & VITALE, M. (2007) Combined analysis of galectin-3 and BRAFV600E improves the accuracy of fine-needle aspiration biopsy with cytological findings suspicious for papillary thyroid carcinoma. *Endocr Relat Cancer*, 14, 1089-97.
- SETHI, K., SARKAR, S., DAS, S., MOHANTY, B. & MANDAL, M. (2010) Biomarkers for the diagnosis of thyroid cancer. *J Exp Ther Oncol*, 8, 341-52.
- SOBRINHO-SIMOES, M., ASA, S. L., KROLL, T. G., NIKIFOROV, Y. E., DELELLIS, R. A., FARID, P., KITAMURA, Y., NOGUCHI, S. U., ENG, C., HARACH, R., WILLIAMS, E. D., SCHNEIDER, A. B., FAGIN, J. A., GHOSSEIN, R. A., MAZZAFERRI, E. L., LLOYD, R. V., LIVOLSI, V. A. & CHAN, J. K. C. (2004) Follicular Carcinoma. IN DELELLIS, R. A., LLOYD, R. V., HEITZ, P. U. & ENG, C. (Eds.) *World Health Organization Classification of Tumours. Pathology & Genetics Tumours of Endocrine*. Lyon, IARC Press, 67-72.
- TAKENAKA, Y., FUKUMORI, T., YOSHII, T., OKA, N., INOHARA, H., KIM, H. R., BRESALIER, R. S. & RAZ, A. (2004) Nuclear export of phosphorylated galectin-3 regulates its antiapoptotic activity in response to chemotherapeutic drugs. *Mol Cell Biol*, 24, 4395-406.
- WEINBERGER, P. M., ADAM, B. L., GOURIN, C. G., MORETZ, W. H., 3RD, BOLLAG, R. J., WANG, B. Y., LIU, Z., LEE, J. R. & TERRIS, D. J. (2007) Association of nuclear, cytoplasmic expression of galectin-3 with beta-catenin/Wnt-pathway activation in thyroid carcinoma. *Arch Otolaryngol Head Neck Surg*, 133, 503-10.

